- Details
- Phil Koo, MD is joined by Wolfgang Weber, MD sharing his thoughts on the current state of PSMA based therapies. Dr. Weber discusses which patients respond well to this treatment, as well as the research being done to better understand why some patients do not respond well to this treatment. Dr. Weber concludes with a glimpse of things to come for PSMA based therapies. Biographies: Wolfgang Weber,...
|
- Details
- Ian Davis, MBBS, PhD, FRACP, and Michael Hofman, MBBS, FRACP, discuss the TheraP trial with Alicia Morgans, MD, MPH, which was presented at the ASCO 2020 virtual meeting. This study showed that in men with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC), LuPSMA was more active than cabazitaxel. Drs. Hofman and Davis provide insights into how Lutetium-PSMA works mechanisti...
|
- Details
- Michael Hofman, from the Peter MacCallum Cancer Centre in Melbourne, Australia joins Charles Ryan to go "beyond the VISION Trial" discussing ongoing clinical trials with lutetium, for example, TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603) where results are...
|
- Details
- Scott Tagawa joins Alicia Morgans in discussing his recent research focus on radiopharmaceuticals for the treatment of prostate cancer. Dr. Tagawa highlights his studies evaluating both beta-emitting particles and alpha targeted particle therapies. Biographies: Scott T. Tagawa, MD, Associate Professor of Clinical Medicine, Clinical Urology, Medical Director, Genitourinary Oncology Research Program...
|
- Details
- Carmel Pezaro and Michael Hofman discuss the evolving role of lutetium-PSMA in the highly personalized treatment strategy for metastatic castrate-resistant prostate cancer in the era of personalized medicine. Michael Hofman discusses the research on 177Lu-DOTA-PSMA-617 (177Lu-PSMA-617), a PSMA-targeted small molecule with favorable properties and is the most extensively investigated PSMA radioliga...
|
- Details
- Where in this treatment regimen would you place lutetium-177-PSMA radioligand therapy? This was the question Harshad Kulkarni, MD posed to the audience at the start of his presentation. The aim of the study which he was presenting during this Society of Nuclear Medicine and Molecular Imaging presentation was to determine the influence of timing of lutetium PSMA radioligand therapy in metastatic pr...
|
- Details
- Panagiotis Vlachostergios, MD, Ph.D., describes a study that he conducted reviewing the outcomes of patients who participated in PSMA targeted radionuclide trials over the past 18 years. Dr. Vlachostergios generated a visual score of PSMA expression to determine an association with response to PSMA-radio-nucleotide targeted therapies. Higher PSMA expressers showed an association with PSA response....
|
- Details
- Professor Michael Hofman presents details of a phase II prospective study on lutetium-PSMA-617. This study used the diagnostic companion of gallium-PSMA-11 to select patients with a high PSMA expression that were suitable for lutetium-PSMA-607 therapy. This was a prospective study. It was a 30 patient study and the results of that initial cohort were published in Lancet Oncology. This was followed...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Oliver Sartor and Michael Morris join Charles to discuss lutetium in advanced prostate cancer and the VISION trial. Dr. Michael Morris serves on the scientific oversight committee of the trial, and Dr. Sartor is one of the co-PIs of this clinical trial. The VISION trial has the potential to change clinical practice in the...
|
- Details
- Professor of Medicine Oliver Sartor from Tulane University joins Charles Ryan to discuss several lutetium studies, radioligand therapy, and the VISION trial and where the state of lutetium currently stands both in the United States and globally with radiopharmaceutical treatment options. Biographies: A. Oliver Sartor, MD, Professor of Medicine and Medical Director, Tulane Cancer Center; C. E. and...
|
